Projects per year
Abstract
HAMLET (human alpha-lactalbumin made lethal to tumor cells), a molecular complex derived from human milk, is an interesting new tool in cancer research since it induces programmed cell death in tumor cells while leaving normal, differentiated cells unharmed.
The in vivo effects of HAMLET were studied in a rat xenograft model of human glioblastoma. HAMLET reduced the tumor volume and delayed the onset of pressure symptoms. Programmed cell death was induced in the tumor, but not in the adjacent normal brain tissue. In non-grafted rats, HAMLET spread throughout the infused brain hemisphere and no significant toxic side-effects were recorded.
The therapeutic effects of HAMLET were investigated further in a placebo-controlled study of patients with skin papillomas. Local application of HAMLET for a three-week period reduced the volume of the papillomas by >75% in all the patients and in 96% of the papillomas as compared with 21% in the placebo-control group. No adverse reactions were reported and there was no difference in outcome for immunosuppressed patients.
A mechanism of tumor-cell death was suggested, one that relates to the partially unfolded state of HAMLET. Massive amounts of HAMLET gained entry into the tumor cells, it interacted with the proteasomes and caused a stress response due to the overload of partially unfolded protein. HAMLET activated the proteasomes in the cytoplasm, but degradation was delayed and fragmentation of the proteasomes was triggered instead. HAMLET and proteasomes translocated to the tumor cell nuclei, where chromatin homeostasis was disrupted. HAMLET-induced tumor-cell death was partially prevented by blocking proteasome activity, supporting the role of proteasomes in cell death.
HAMLET represents a new approach to cancer therapy, having therapeutic effects in vivo and targeting cell death pathways that are susceptible for activation in tumor cells, thus circumventing the roadblocks that prevent cell death in many tumor cells.
The in vivo effects of HAMLET were studied in a rat xenograft model of human glioblastoma. HAMLET reduced the tumor volume and delayed the onset of pressure symptoms. Programmed cell death was induced in the tumor, but not in the adjacent normal brain tissue. In non-grafted rats, HAMLET spread throughout the infused brain hemisphere and no significant toxic side-effects were recorded.
The therapeutic effects of HAMLET were investigated further in a placebo-controlled study of patients with skin papillomas. Local application of HAMLET for a three-week period reduced the volume of the papillomas by >75% in all the patients and in 96% of the papillomas as compared with 21% in the placebo-control group. No adverse reactions were reported and there was no difference in outcome for immunosuppressed patients.
A mechanism of tumor-cell death was suggested, one that relates to the partially unfolded state of HAMLET. Massive amounts of HAMLET gained entry into the tumor cells, it interacted with the proteasomes and caused a stress response due to the overload of partially unfolded protein. HAMLET activated the proteasomes in the cytoplasm, but degradation was delayed and fragmentation of the proteasomes was triggered instead. HAMLET and proteasomes translocated to the tumor cell nuclei, where chromatin homeostasis was disrupted. HAMLET-induced tumor-cell death was partially prevented by blocking proteasome activity, supporting the role of proteasomes in cell death.
HAMLET represents a new approach to cancer therapy, having therapeutic effects in vivo and targeting cell death pathways that are susceptible for activation in tumor cells, thus circumventing the roadblocks that prevent cell death in many tumor cells.
Original language | English |
---|---|
Qualification | Doctor |
Awarding Institution |
|
Supervisors/Advisors |
|
Award date | 2005 May 20 |
Publisher | |
ISBN (Print) | 91-85439-50-9 |
Publication status | Published - 2005 |
Bibliographical note
Defence detailsDate: 2005-05-20
Time: 13:00
Place: The GK lecture hall, Biomedical Center, Lund, Sweden.
External reviewer(s)
Name: Heldin, Carl-Henrik
Title: Professor
Affiliation: Ludwig Institute for Cancer Research, Uppsala, Sweden
---
<div class="article_info">W Fischer, L Gustafsson, A.K. Mossberg, J Gronli, S Mork, R Bjerkvig and C Svanborg. <span class="article_issue_date">2004</span>. <span class="article_title">Human Alpha-Lactalbumin Made Lethal to Tumor Cells (HAMLET) Kills Human Glioblastoma Cells in Brain Xenografts by an Apoptosis-Like Mechanism and Prolongs Survival.</span> <span class="journal_series_title">Cancer Res</span>, <span class="journal_volume">vol 64</span> <span class="journal_pages">pp 2105-2112</span>.</div>
<div class="article_info">L Gustafsson, I Leijonhufvud, A Aronsson, A.K. Mossberg and C Svanborg. <span class="article_issue_date">2004</span>. <span class="article_title">Treatment of Skin Papillomas with Topical Alpha-Lactalbumin-Oleic Acid.</span> <span class="journal_series_title">N Engl J Med</span>, <span class="journal_volume">vol 350</span> <span class="journal_pages">pp 2663-2672. acc edit 2639-2642</span>.</div>
<div class="article_info">L Gustafsson, O Hallgren and C Svanborg. <span class="article_issue_date"></span>. <span class="article_title">Unfolded Protein Overload, Proteasome Activation and Death in HAMLET-Treated Tumor Cells.</span> (submitted)</div>
Subject classification (UKÄ)
- Immunology in the Medical Area (including Cell and Immunotherapy)
- Microbiology in the Medical Area
Free keywords
- Biomedicinska vetenskaper
- Biomedical sciences
- proteasome stress
- HAMLET
- human milk
- tumor-cell death
- clinical trial
- rat xenograft model
- skin papilloma
- glioblastoma
Fingerprint
Dive into the research topics of 'HAMLET - In vivo effects and mechanisms of tumor-cell death'. Together they form a unique fingerprint.Projects
- 1 Finished
-
HAMLET- In vivo effects and mechanisms of tumor cells death
Gustafsson, L. (Researcher)
2000/09/01 → 2008/09/01
Project: Dissertation
Activities
- 1 Media participation
-
Medverkande i "Fråga doktorn" på Tv avseende avhandlingsarbete
Gustafsson, L. (Contributor)
2004Activity: Other › Media participation